- Home
- MGNX vs APT Comparison
MGNX vs APT Comparison
Compare MGNX & APT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- APT
- Stock Information
- Founded
- MGNX 2000
- APT 1983
- Country
- MGNX United States
- APT Canada
- Employees
- MGNX N/A
- APT N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- APT
- Sector
- MGNX Health Care
- APT
- Exchange
- MGNX Nasdaq
- APT Nasdaq
- Market Cap
- MGNX 87.7M
- APT 50.5M
- IPO Year
- MGNX 2013
- APT 1995
- Fundamental
- Price
- MGNX $1.33
- APT $4.70
- Analyst Decision
- MGNX Hold
- APT
- Analyst Count
- MGNX 9
- APT 0
- Target Price
- MGNX $5.33
- APT N/A
- AVG Volume (30 Days)
- MGNX 2.0M
- APT 38.1K
- Earning Date
- MGNX 08-05-2025
- APT 08-06-2025
- Dividend Yield
- MGNX N/A
- APT N/A
- EPS Growth
- MGNX N/A
- APT 2.28
- EPS
- MGNX N/A
- APT 0.36
- Revenue
- MGNX $154,050,000.00
- APT $58,180,000.00
- Revenue This Year
- MGNX N/A
- APT N/A
- Revenue Next Year
- MGNX N/A
- APT N/A
- P/E Ratio
- MGNX N/A
- APT $13.17
- Revenue Growth
- MGNX 255.31
- APT N/A
- 52 Week Low
- MGNX $0.99
- APT $4.06
- 52 Week High
- MGNX $5.77
- APT $6.44
- Technical
- Relative Strength Index (RSI)
- MGNX 41.45
- APT 54.21
- Support Level
- MGNX $1.33
- APT $4.54
- Resistance Level
- MGNX $2.17
- APT $4.72
- Average True Range (ATR)
- MGNX 0.17
- APT 0.21
- MACD
- MGNX -0.02
- APT -0.01
- Stochastic Oscillator
- MGNX 2.38
- APT 35.21
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About APT Alpha Pro Tech Ltd.
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.